News Column

NeuroVision Imaging Eye Test Finds Potential for Early Detection of Alzheimer's Disease

July 17, 2014

NeuroVision Imaging reported that preliminary results of a major clinical trial show the company's investigational noninvasive imaging system appeared to detect changes associated with Alzheimer's disease with a simple eye test.

According to a release from the company, the blinded clinical trial of 200 subjects is designed to correlate retinal plaque detected by NeuroVision's noninvasive imaging test with brain plaque considered to be a hallmark sign of Alzheimer's disease, using positron emission tomography, or PET, which is the current standard for clinical trials. Preliminary results of 40 patients showed that beta-amyloid levels detected in the retina with a simple eye test were significantly correlated with beta-amyloid levels in the brain that appeared using PET imaging. The retinal amyloid imaging test differentiated between Alzheimer's and non-Alzheimer's subjects with 100 percent sensitivity and 80.6 percent specificity. Beta-amyloid protein is the primary material found in brain plaques characteristic of Alzheimer's disease. With the ability to detect plaques on the order of 20 microns, the test offers great promise for early detection.

Additionally, longitudinal studies on an initial cohort of patients demonstrated an average of 3.5 percent increase in retinal amyloid over a 3.5-month period of time. These initial findings have led to strong interest from several pharmaceutical companies and subsequent participation in therapeutic clinical trials in the hopes of further test validation, monitoring of progression over a short period of time, and assessment of therapeutic effectiveness.

"If longitudinal studies demonstrate that our test can detect changes in retinal plaque over a short period of time, we see great potential for using the technology not just for early detection, but also for measuring response to therapy," said NeuroVision CEO Steven Verdooner. "Tests currently used in clinical trials such as PET scan and measurement of amyloid and tau in CSF are invasive, expensive, and not conducive to repeated tests. We believe the ability to measure progression is very powerful and are engaging in partnerships for therapeutic trials to prove that out."

"The unfortunate reality today is that Alzheimer's disease is detected far too late for patients and their loved ones. While further study is needed, these preliminary results hold promise for the development of an easy exam that can detect disease sooner, paving the way for earlier interventions with new therapies," Frost said.

NeuroVision Imaging develops digital imaging, and diagnostic solutions for Alzheimer's disease and eye care markets.

More information and complete details:

www.neurovision.com

((Comments on this story may be sent to newsdesk@closeupmedia.com))


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Health & Beauty Close - Up


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters